Ironwood Pharmaceuticals, Inc., a prominent player in the biotechnology sector, is headquartered in Boston, Massachusetts. The company is dedicated to the discovery, development, manufacturing, and commercialization of pharmaceuticals aimed at treating a range of conditions, including cholesterol, gastrointestinal, cardiovascular diseases, pain, inflammation, and other related health issues. Ironwood Pharmaceuticals’ stock is actively traded on the Nasdaq stock exchange, reflecting its significant presence in the healthcare industry.
As of February 11, 2026, Ironwood Pharmaceuticals’ stock closed at $4.61. The company’s stock has experienced notable volatility over the past year, with a 52-week high of $5.78 recorded on January 1, 2026, and a 52-week low of $0.53 on May 15, 2025. This wide range underscores the dynamic nature of the biotechnology sector and the stock market’s response to various factors influencing the company’s performance.
The company’s market capitalization stands at approximately $749.95 million USD, indicating its substantial scale within the industry. However, the financial metrics reveal some challenges. The price-to-earnings (P/E) ratio is currently 27.39, suggesting that investors are willing to pay a premium for the company’s earnings potential. Conversely, the price-to-book (P/B) ratio is negative at –2.81, indicating that the market valuation is below the company’s book value. This discrepancy may reflect investor concerns about the company’s future growth prospects or profitability.
Recent market activity includes a transaction by Harbor Capital Advisors, Inc., which sold 135 shares of Ironwood Pharmaceuticals on January 20, 2026. This sale is part of the broader trading activity surrounding the company’s stock. As of the latest updates, there have been no additional corporate announcements from Ironwood Pharmaceuticals, suggesting a period of relative stability in terms of public disclosures.
For more detailed information about Ironwood Pharmaceuticals and its product offerings, stakeholders and interested parties are encouraged to visit the company’s official website at www.ironwoodpharma.com . This resource provides comprehensive insights into the company’s strategic initiatives, research developments, and market positioning within the healthcare sector.
